Ultragenyx Pharmaceutical Inc.
RARE · XNASCIK 1515673fmd_05WHSA5VP05HDWX8DP3ZQAA0SVManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2012 to Sep 30, 2026, 56 periods
Latest annual · FY2025
Millions- Total revenues
- 673
- Operating income
- (535)
- Net income
- (575)
- Free cash flow
- (472)
Latest quarter · Q3 FY2026
Millions- Total revenues
- 173
- Operating income
- (110)
- Net income
- (118)
- Free cash flow
- (45)
Daily close · RAREIEX trades only
Nov 13, 2025 to Nov 11, 2026 · 250 sessions16.70 USD
Built from trades executed at IEX only, one exchange with a small share of US volume. This is not the consolidated tape. The close is the last IEX trade of the session, not the official closing price. Earlier sessions are divided by the later split ratios the API confirmed against IEX prices; dividends are not adjusted. Switch to As traded for the prices as they printed. End of day, not real time: a session is published the day after it trades.
Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. iex.io/legal/hist-data-terms
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2022 to FY2025
- +22.8%
- Revenue, 5 yearsFY2020 to FY2025
- +19.9%
- Net income, 5 yearsFY2020 to FY2025
- n/m
Ultragenyx Pharmaceutical Inc. (RARE) financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2025 | FY2024 | Change | Source |
|---|---|---|---|---|
| Revenue | $673 million | $560 million | +20.2% | 10-K 2026-02-18 · proof |
| Operating income | -$535 million | -$536 million | 10-K 2026-02-18 · proof | |
| Net income | -$575 million | -$569 million | 10-K 2026-02-18 · proof | |
| Cash from operating activities | -$466 million | -$414 million | 10-K 2026-02-18 · proof | |
| Free cash flow | -$472 million | -$421 million | 10-K 2026-02-18 · proof | |
| Total assets | $1.5 billion | $1.5 billion | +1.9% | 10-K 2026-02-18 · proof |
| Total liabilities | $1.6 billion | $1.2 billion | +29.3% | 10-K 2026-02-18 · proof |
| Cash and cash equivalents | $421 million | $174 million | +142% | 10-K 2026-02-18 · proof |
- What was Ultragenyx Pharmaceutical Inc. (RARE)'s revenue in fiscal 2025?
- Ultragenyx Pharmaceutical Inc. (RARE) reported revenue of $673 million for fiscal 2025 (the year ended Dec 31, 2025), against $560 million the year before (+20.2%). Source: the 10-K filed with the SEC on Feb 18, 2026. SEC
- What was Ultragenyx Pharmaceutical Inc. (RARE)'s operating income in fiscal 2025?
- Ultragenyx Pharmaceutical Inc. (RARE) reported operating income of -$535 million for fiscal 2025 (the year ended Dec 31, 2025), against -$536 million the year before. Source: the 10-K filed with the SEC on Feb 18, 2026. SEC
- What was Ultragenyx Pharmaceutical Inc. (RARE)'s net income in fiscal 2025?
- Ultragenyx Pharmaceutical Inc. (RARE) reported net income of -$575 million for fiscal 2025 (the year ended Dec 31, 2025), against -$569 million the year before. Source: the 10-K filed with the SEC on Feb 18, 2026. SEC
- What was Ultragenyx Pharmaceutical Inc. (RARE)'s cash from operating activities in fiscal 2025?
- Ultragenyx Pharmaceutical Inc. (RARE) reported cash from operating activities of -$466 million for fiscal 2025 (the year ended Dec 31, 2025), against -$414 million the year before. Source: the 10-K filed with the SEC on Feb 18, 2026. SEC
- What was Ultragenyx Pharmaceutical Inc. (RARE)'s free cash flow in fiscal 2025?
- Ultragenyx Pharmaceutical Inc. (RARE) reported free cash flow of -$472 million for fiscal 2025 (the year ended Dec 31, 2025), against -$421 million the year before. Source: the 10-K filed with the SEC on Feb 18, 2026. SEC
- What are Ultragenyx Pharmaceutical Inc. (RARE)'s total assets?
- As of Dec 31, 2025, Ultragenyx Pharmaceutical Inc. (RARE) reported total assets of $1.5 billion, against $1.5 billion a year earlier (+1.9%). Source: the 10-K filed with the SEC on Feb 18, 2026. SEC
- What are Ultragenyx Pharmaceutical Inc. (RARE)'s total liabilities?
- As of Dec 31, 2025, Ultragenyx Pharmaceutical Inc. (RARE) reported total liabilities of $1.6 billion, against $1.2 billion a year earlier (+29.3%). Source: the 10-K filed with the SEC on Feb 18, 2026. SEC
- What are Ultragenyx Pharmaceutical Inc. (RARE)'s cash and cash equivalents?
- As of Dec 31, 2025, Ultragenyx Pharmaceutical Inc. (RARE) reported cash and cash equivalents of $421 million, against $174 million a year earlier (+142%). Source: the 10-K filed with the SEC on Feb 18, 2026. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:RARE&period_type=annual&limit=5"Information only, not investment advice.